American Society of Hematology, Blood, 1(124), p. 121-133, 2014
DOI: 10.1182/blood-2013-11-538819
Full text: Download
Key Points SIRT1 is highly expressed in subsets of patients with acute myeloid leukemia harboring activating mutations in signaling pathways and is regulated at the protein levels. Targeting SIRT1 sensitizes leukemic blast to tyrosine kinase inhibitor treatment or chemotherapy via restoration of p53 activity.